Obesity Drugs' Next Wave: These Companies Could Snag 20% of GLP-1 Market, Analysts Say
Novo Nordisk has submitted an application for the new indication of "Simeglutide" to be listed in China.
On August 26, the latest announcement on the CDE official website disclosed that novo-nordisk a/s's application for marketing approval of Semaglutide injection for a new indication has been accepted, with no specific indication information disclosed yet.
There are many followers in the weight loss drug market, but Novo Nordisk (NVO.US) and Eli Lilly (LLY.US) will maintain a "two-horse race" situation.
Although other pharmaceutical companies are also preparing to launch GLP-1 class weight-loss drugs, they are unlikely to have a significant impact on the current dominant market positions of novo-nordisk a/s and eli lilly and co.
Why Viking Therapeutics Is Thriving in the $150 Billion Weight Loss Drug Market
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Green Dragon 2024 : That makes total sense. Especially, when Tom Lee stated that there should be a 40% growth in the small caps (Russell). Great information thank you!